Multicentre phase 2 study of neoadjuvant oxaliplatin and capecitabine followed by chemo-radiotherapy in patients with locally advanced carcinoma of esphago-gastric junction.
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms INOX-EGJ
- 15 Feb 2018 Status changed from recruiting to discontinued.
- 02 Jul 2014 New trial record